Your browser doesn't support javascript.
loading
Rare deleterious germline variants and risk of lung cancer.
Liu, Yanhong; Xia, Jun; McKay, James; Tsavachidis, Spiridon; Xiao, Xiangjun; Spitz, Margaret R; Cheng, Chao; Byun, Jinyoung; Hong, Wei; Li, Yafang; Zhu, Dakai; Song, Zhuoyi; Rosenberg, Susan M; Scheurer, Michael E; Kheradmand, Farrah; Pikielny, Claudio W; Lusk, Christine M; Schwartz, Ann G; Wistuba, Ignacio I; Cho, Michael H; Silverman, Edwin K; Bailey-Wilson, Joan; Pinney, Susan M; Anderson, Marshall; Kupert, Elena; Gaba, Colette; Mandal, Diptasri; You, Ming; de Andrade, Mariza; Yang, Ping; Liloglou, Triantafillos; Davies, Michael P A; Lissowska, Jolanta; Swiatkowska, Beata; Zaridze, David; Mukeria, Anush; Janout, Vladimir; Holcatova, Ivana; Mates, Dana; Stojsic, Jelena; Scelo, Ghislaine; Brennan, Paul; Liu, Geoffrey; Field, John K; Hung, Rayjean J; Christiani, David C; Amos, Christopher I.
Affiliation
  • Liu Y; Dan L. Duncan Comprehensive Cancer Center, Department of Medicine, Baylor College of Medicine, Houston, TX, USA.
  • Xia J; Institute for Clinical and Translational Research, Baylor College of Medicine, Houston, TX, USA.
  • McKay J; International Agency for Research on Cancer, Lyon, France.
  • Tsavachidis S; Dan L. Duncan Comprehensive Cancer Center, Department of Medicine, Baylor College of Medicine, Houston, TX, USA.
  • Xiao X; Institute for Clinical and Translational Research, Baylor College of Medicine, Houston, TX, USA.
  • Spitz MR; Dan L. Duncan Comprehensive Cancer Center, Department of Medicine, Baylor College of Medicine, Houston, TX, USA.
  • Cheng C; Dan L. Duncan Comprehensive Cancer Center, Department of Medicine, Baylor College of Medicine, Houston, TX, USA.
  • Byun J; Institute for Clinical and Translational Research, Baylor College of Medicine, Houston, TX, USA.
  • Hong W; Dan L. Duncan Comprehensive Cancer Center, Department of Medicine, Baylor College of Medicine, Houston, TX, USA.
  • Li Y; Institute for Clinical and Translational Research, Baylor College of Medicine, Houston, TX, USA.
  • Zhu D; Institute for Clinical and Translational Research, Baylor College of Medicine, Houston, TX, USA.
  • Song Z; Dan L. Duncan Comprehensive Cancer Center, Department of Medicine, Baylor College of Medicine, Houston, TX, USA.
  • Rosenberg SM; Institute for Clinical and Translational Research, Baylor College of Medicine, Houston, TX, USA.
  • Scheurer ME; Institute for Clinical and Translational Research, Baylor College of Medicine, Houston, TX, USA.
  • Kheradmand F; Institute for Clinical and Translational Research, Baylor College of Medicine, Houston, TX, USA.
  • Pikielny CW; Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, USA.
  • Lusk CM; Dan L. Duncan Comprehensive Cancer Center, Department of Medicine, Baylor College of Medicine, Houston, TX, USA.
  • Schwartz AG; Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA.
  • Wistuba II; Dan L. Duncan Comprehensive Cancer Center, Department of Medicine, Baylor College of Medicine, Houston, TX, USA.
  • Cho MH; Michael E. DeBakey Veterans Affairs Medical Center, Houston, TX, USA.
  • Silverman EK; Department of Biomedical Data Science, Geisel School of Medicine, Dartmouth College, Lebanon, NH, USA.
  • Bailey-Wilson J; Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA.
  • Pinney SM; Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA.
  • Anderson M; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Kupert E; Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
  • Gaba C; Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
  • Mandal D; National Human Genome Research Institute, Bethesda, MD, USA.
  • You M; University of Cincinnati College of Medicine, Cincinnati, OH, USA.
  • de Andrade M; University of Cincinnati College of Medicine, Cincinnati, OH, USA.
  • Yang P; University of Cincinnati College of Medicine, Cincinnati, OH, USA.
  • Liloglou T; The University of Toledo College of Medicine, Toledo, OH, USA.
  • Davies MPA; Louisiana State University Health Sciences Center, New Orleans, LA, USA.
  • Lissowska J; Medical College of Wisconsin, Milwaukee, WI, USA.
  • Swiatkowska B; Mayo Clinic College of Medicine, Rochester, MN, USA.
  • Zaridze D; Mayo Clinic College of Medicine, Scottsdale, AZ, USA.
  • Mukeria A; Roy Castle Lung Cancer Research Programme, The University of Liverpool, Department of Molecular and Clinical Cancer Medicine, Liverpool, UK.
  • Janout V; Roy Castle Lung Cancer Research Programme, The University of Liverpool, Department of Molecular and Clinical Cancer Medicine, Liverpool, UK.
  • Holcatova I; M. Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland.
  • Mates D; Nofer Institute of Occupational Medicine, Department of Environmental Epidemiology, Lodz, Poland.
  • Stojsic J; Russian N.N. Blokhin Cancer Research Centre, Moscow, Russian Federation.
  • Scelo G; Russian N.N. Blokhin Cancer Research Centre, Moscow, Russian Federation.
  • Brennan P; Faculty of Health Sciences, Palacky University, Olomouc, Czech Republic.
  • Liu G; Institute of Public Health and Preventive Medicine, Charles University, 2nd Faculty of Medicine, Prague, Czech Republic.
  • Field JK; National Institute of Public Health, Bucharest, Romania.
  • Hung RJ; Department of Thoracopulmonary Pathology, Service of Pathology, Clinical Center of Serbia, Belgrade, Serbia.
  • Christiani DC; International Agency for Research on Cancer, Lyon, France.
  • Amos CI; International Agency for Research on Cancer, Lyon, France.
NPJ Precis Oncol ; 5(1): 12, 2021 Feb 16.
Article in En | MEDLINE | ID: mdl-33594163
Recent studies suggest that rare variants exhibit stronger effect sizes and might play a crucial role in the etiology of lung cancers (LC). Whole exome plus targeted sequencing of germline DNA was performed on 1045 LC cases and 885 controls in the discovery set. To unveil the inherited causal variants, we focused on rare and predicted deleterious variants and small indels enriched in cases or controls. Promising candidates were further validated in a series of 26,803 LCs and 555,107 controls. During discovery, we identified 25 rare deleterious variants associated with LC susceptibility, including 13 reported in ClinVar. Of the five validated candidates, we discovered two pathogenic variants in known LC susceptibility loci, ATM p.V2716A (Odds Ratio [OR] 19.55, 95%CI 5.04-75.6) and MPZL2 p.I24M frameshift deletion (OR 3.88, 95%CI 1.71-8.8); and three in novel LC susceptibility genes, POMC c.*28delT at 3' UTR (OR 4.33, 95%CI 2.03-9.24), STAU2 p.N364M frameshift deletion (OR 4.48, 95%CI 1.73-11.55), and MLNR p.Q334V frameshift deletion (OR 2.69, 95%CI 1.33-5.43). The potential cancer-promoting role of selected candidate genes and variants was further supported by endogenous DNA damage assays. Our analyses led to the identification of new rare deleterious variants with LC susceptibility. However, in-depth mechanistic studies are still needed to evaluate the pathogenic effects of these specific alleles.

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Etiology_studies / Prognostic_studies / Risk_factors_studies Language: En Journal: NPJ Precis Oncol Year: 2021 Document type: Article Affiliation country: United States Country of publication: United kingdom

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Etiology_studies / Prognostic_studies / Risk_factors_studies Language: En Journal: NPJ Precis Oncol Year: 2021 Document type: Article Affiliation country: United States Country of publication: United kingdom